HHS IG subpoenas Procrit documents
Executive Summary
Johnson & Johnson is responding to a subpoena from HHS' Office of Inspector General for documents related to the sales and marketing of the anemia treatment Procrit (epoetin alfa). The company said it received the subpoena Sept. 30 and is cooperating in responding to it. Procrit marketing is also under scrutiny by New York Attorney General Eliot Spitzer (1"The Pink Sheet" DAILY, Aug. 5, 2004)...
You may also be interested in...
J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation
Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.